US5814651A
(en)
|
1992-12-02 |
1998-09-29 |
Pfizer Inc. |
Catechol diethers as selective PDEIV inhibitors
|
US5750349A
(en)
|
1993-01-25 |
1998-05-12 |
Takeda Chemical Industries Ltd. |
Antibodies to β-amyloids or their derivatives and use thereof
|
JPH08295667A
(ja)
*
|
1995-04-27 |
1996-11-12 |
Takeda Chem Ind Ltd |
複素環化合物、その製造法および剤
|
JPH08295687A
(ja)
*
|
1995-04-28 |
1996-11-12 |
Ube Ind Ltd |
無水シトラコン酸の製造法
|
DE19709877A1
(de)
|
1997-03-11 |
1998-09-17 |
Bayer Ag |
1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
|
ATE402717T1
(de)
|
1997-04-09 |
2008-08-15 |
Intellect Neurosciences Inc |
Für die termini des beta-amyloids spezifische, rekombinante antikörper, dafür kodierende dna und verfahren zu ihrer verwendung
|
US8173127B2
(en)
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
GB9722520D0
(en)
|
1997-10-24 |
1997-12-24 |
Pfizer Ltd |
Compounds
|
US6743427B1
(en)
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
TWI239847B
(en)
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
CZ27399A3
(cs)
|
1999-01-26 |
2000-08-16 |
Ústav Experimentální Botaniky Av Čr |
Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
|
BR9916746A
(pt)
*
|
1999-06-03 |
2005-01-11 |
Abbott Lab |
Compostos anti-inflamatórios que inibem adesão de célula
|
NZ515418A
(en)
|
1999-06-28 |
2003-11-28 |
Janssen Pharmaceutica Nv |
Respiratory syncytial virus replication inhibitors
|
ATE322494T1
(de)
|
2000-01-07 |
2006-04-15 |
Universitaire Instelling Antwe |
Purin derivate, ihre herstellung und verwendung
|
SK288711B6
(sk)
|
2000-02-24 |
2019-11-05 |
Univ Washington |
Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
|
ATE300540T1
(de)
|
2000-04-27 |
2005-08-15 |
Yamanouchi Pharma Co Ltd |
Imidazopyridin-derivate
|
DE10045112A1
(de)
|
2000-09-11 |
2002-03-21 |
Merck Patent Gmbh |
Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
|
EP1335738A4
(en)
|
2000-11-03 |
2004-09-08 |
Proteotech Inc |
METHODS OF ISOLATING AMYLOID INHIBITOR COMPOUNDS AND USE OF COMPOUNDS USED FROM UNCARIA TOMENTOSA AND PARENT PLANTS
|
GB0115181D0
(en)
|
2001-06-20 |
2001-08-15 |
Glaxo Group Ltd |
Novel use
|
WO2003000697A1
(fr)
|
2001-06-22 |
2003-01-03 |
Takeda Chemical Industries, Ltd. |
Derive de furo-isoquinoline, procede de production de ce compose et utilisation de ce compose
|
DE60204463T2
(de)
|
2001-06-27 |
2006-05-18 |
Merck Frosst Canada & Co, Kirkland |
Substituierte 8-Arylchinoline als PDE4-Hemmer
|
KR20040017246A
(ko)
|
2001-06-29 |
2004-02-26 |
니켄 가가쿠 가부시키가이샤 |
사이클로알케논 유도체
|
WO2003008396A1
(fr)
|
2001-07-16 |
2003-01-30 |
Nikken Chemicals Co., Ltd. |
Derive d'oxazine actif sur le plan optique
|
BR0211209A
(pt)
|
2001-07-18 |
2004-07-13 |
Merck Patent Gmbh |
Derivados de 4-(benzilidenoamino)-3-(metilsulfanil)-4h-1,2,4-triazin- 5-ona tendo uma ação antagonìstica de tnf e inibição de pde iv para o tratamento de doenças cardìacas e alergias
|
WO2003008373A1
(de)
|
2001-07-19 |
2003-01-30 |
Merck Patent Gmbh |
Tyrosinhydrazide
|
FR2827599A1
(fr)
|
2001-07-20 |
2003-01-24 |
Neuro3D |
Composes derives de quinoleine et quinoxaline,preparation et utilisations
|
GB0118373D0
(en)
|
2001-07-27 |
2001-09-19 |
Glaxo Group Ltd |
Novel therapeutic method
|
TWI221838B
(en)
|
2001-08-09 |
2004-10-11 |
Tanabe Seiyaku Co |
Pyrazinoisoquinoline compound or naphthalene compound
|
EP1285922A1
(en)
|
2001-08-13 |
2003-02-26 |
Warner-Lambert Company |
1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
|
FR2828693B1
(fr)
|
2001-08-14 |
2004-06-18 |
Exonhit Therapeutics Sa |
Nouvelle cible moleculaire de la neurotoxicite
|
AU2002333193A1
(en)
|
2001-08-15 |
2003-03-03 |
Leo Pharma A/S |
A pharmaceutical composition for dermal application
|
MXPA04001353A
(es)
|
2001-08-15 |
2004-10-27 |
Icos Corp |
2h-ftalazin-1-onas y metodos para su uso.
|
WO2003016466A2
(en)
|
2001-08-17 |
2003-02-27 |
Eli Lilly And Company |
ANTI-Aβ ANTIBODIES
|
JO2311B1
(en)
|
2001-08-29 |
2005-09-12 |
ميرك فروست كندا ليمتد |
Alkyl inhibitors Ariel phosphodiesterase-4
|
GB0122031D0
(en)
|
2001-09-12 |
2001-10-31 |
Pfizer Ltd |
Use of pde4 inhibitors in a dry powder inhaler
|
ATE349243T1
(de)
|
2001-09-19 |
2007-01-15 |
Altana Pharma Ag |
Kombination von einem pde-hemmer und eines leukotrien rezeptor antagonisten
|
DK1429807T3
(da)
|
2001-09-19 |
2007-06-18 |
Altana Pharma Ag |
Kombination af et NSAID og en PDE4-inhibitor
|
WO2003035650A1
(fr)
|
2001-09-25 |
2003-05-01 |
Takeda Chemical Industries, Ltd. |
Inhibiteur d'entree
|
NZ531786A
(en)
|
2001-10-02 |
2006-10-27 |
Upjohn Co |
Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
|
GB0123951D0
(en)
|
2001-10-05 |
2001-11-28 |
Glaxo Group Ltd |
Therapies for treating respiratory diseases
|
DE10150517A1
(de)
|
2001-10-12 |
2003-04-17 |
Merck Patent Gmbh |
Verwendung von Phosphodiesterase IV-Inhibitoren
|
CN1604776A
(zh)
|
2001-10-16 |
2005-04-06 |
记忆药物公司 |
作为用于治疗神经病综合症的pde-4抑制剂的4-(4-烷氧基-3-羟基苯基)-2-吡咯烷酮衍生物
|
EP2336133A1
(en)
|
2001-10-30 |
2011-06-22 |
Conforma Therapeutics Corporation |
Purine analogs having HSP90-inhibiting activity
|
SK1862004A3
(en)
|
2001-10-31 |
2004-08-03 |
|
Type 4 phosphodiesterase inhibitors and uses thereof
|
EP1506196B1
(en)
|
2001-11-01 |
2012-01-18 |
Icagen, Inc. |
Pyrazolopyrimidines as sodium channel inhibitors
|
US20030195205A1
(en)
|
2001-11-02 |
2003-10-16 |
Pfizer Inc. |
PDE9 inhibitors for treating cardiovascular disorders
|
ATE335486T1
(de)
|
2001-11-05 |
2006-09-15 |
Merck Patent Gmbh |
Hydrazono-malonitrile
|
AR037517A1
(es)
|
2001-11-05 |
2004-11-17 |
Novartis Ag |
Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
|
US20030092706A1
(en)
|
2001-11-09 |
2003-05-15 |
Johannes Barsig |
Combination
|
IS7221A
(is)
|
2001-11-15 |
2004-04-15 |
Memory Pharmaceuticals Corporation |
Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
|
FR2832711B1
(fr)
|
2001-11-26 |
2004-01-30 |
Warner Lambert Co |
Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
|
US20050101000A1
(en)
|
2002-12-11 |
2005-05-12 |
Isis Pharmaceuticals Inc. |
Modulation of phosphodiesterase 4B expression
|
DE10238723A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Phenyl-substituierte Pyrazolyprimidine
|
DE10238724A1
(de)
|
2002-08-23 |
2004-03-04 |
Bayer Ag |
Alkyl-substituierte Pyrazolpyrimidine
|
BR0315157A
(pt)
|
2002-10-09 |
2005-08-09 |
Rinat Neuroscience Corp |
Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
|
WO2004042390A2
(en)
|
2002-11-08 |
2004-05-21 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
|
AU2003299651A1
(en)
|
2002-12-11 |
2004-06-30 |
Merck And Co., Inc. |
Tyrosine kinase inhibitors
|
DE602004025220D1
(de)
|
2003-04-11 |
2010-03-11 |
High Point Pharmaceuticals Llc |
Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen
|
WO2004089471A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
|
US20040220186A1
(en)
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
US7741341B2
(en)
|
2003-05-19 |
2010-06-22 |
Sanofi-Aventis Deutschland Gmbh |
Benzimidazole-derivatives as factor Xa inhibitors
|
EP1638935A1
(en)
|
2003-06-19 |
2006-03-29 |
Pfizer Products Inc. |
Nk1 antagonist
|
CA2530081A1
(en)
|
2003-07-01 |
2005-01-13 |
Merck & Co., Inc. |
Ophthalmic compositions for treating ocular hypertension
|
FR2857966A1
(fr)
|
2003-07-24 |
2005-01-28 |
Aventis Pharma Sa |
Produits aryl-heteroaromatiques, compositions les contenant et utilisation
|
US20050020587A1
(en)
|
2003-07-25 |
2005-01-27 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
CA2538220A1
(en)
|
2003-09-09 |
2005-03-24 |
Takeda Pharmaceutical Company Limited |
Use of antibody
|
GB0322722D0
(en)
|
2003-09-27 |
2003-10-29 |
Glaxo Group Ltd |
Compounds
|
GB0322726D0
(en)
|
2003-09-27 |
2003-10-29 |
Glaxo Group Ltd |
Compounds
|
NZ546521A
(en)
|
2003-09-29 |
2009-09-25 |
Topigen Pharma Inc |
Oligonucleotide compositions and methods for treating disease including inflammatory conditions
|
GB0327319D0
(en)
|
2003-11-24 |
2003-12-24 |
Pfizer Ltd |
Novel pharmaceuticals
|
WO2005066151A2
(en)
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
WO2005080361A1
(en)
|
2004-02-02 |
2005-09-01 |
Pfizer Products Inc. |
Histamine-3 receptor modulators
|
WO2006078287A2
(en)
|
2004-05-06 |
2006-07-27 |
Plexxikon, Inc. |
Pde4b inhibitors and uses therefor
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
EP1595881A1
(en)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
|
GEP20115195B
(en)
|
2004-07-30 |
2011-04-11 |
Rinat Neuroscience Corp |
Antibodies directed against amyloid-beta peptide and use thereof
|
EP1786813A2
(en)
|
2004-09-03 |
2007-05-23 |
Plexxikon, Inc. |
Bicyclic heteroaryl pde4b inhibitors
|
GB0420719D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
CN101083986A
(zh)
|
2004-09-20 |
2007-12-05 |
泽农医药公司 |
双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
|
CN101083985A
(zh)
|
2004-09-21 |
2007-12-05 |
幸讬制药公司 |
用于炎症及免疫相关用途的化合物
|
FR2877015B1
(fr)
|
2004-10-21 |
2007-10-26 |
Commissariat Energie Atomique |
Revetement nanostructure et procede de revetement.
|
DE102004054634A1
(de)
*
|
2004-11-12 |
2006-05-18 |
Schwarz Pharma Ag |
Azaindolcarboxamide
|
US20090074775A1
(en)
|
2004-12-22 |
2009-03-19 |
David Michael Holtzman |
Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
|
WO2006088246A1
(ja)
|
2005-02-18 |
2006-08-24 |
Takeda Pharmaceutical Company Limited |
Gpr34受容体機能調節剤
|
GB0503955D0
(en)
|
2005-02-25 |
2005-04-06 |
Glaxo Group Ltd |
Novel compounds
|
PE20061323A1
(es)
|
2005-04-29 |
2007-02-09 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
|
WO2006120552A2
(en)
|
2005-05-12 |
2006-11-16 |
Pfizer Inc. |
ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE
|
CA2608672A1
(en)
|
2005-05-24 |
2006-11-30 |
Pharmacia & Upjohn Company Llc |
Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
|
WO2006126081A2
(en)
|
2005-05-24 |
2006-11-30 |
Pharmacia & Upjohn Company Llc |
Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
|
WO2006126083A1
(en)
|
2005-05-24 |
2006-11-30 |
Pharmacia & Upjohn Company Llc |
Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
|
JP2008543923A
(ja)
|
2005-06-22 |
2008-12-04 |
ファイザー・プロダクツ・インク |
ヒスタミン−3受容体アンタゴニスト
|
US8158673B2
(en)
|
2005-10-27 |
2012-04-17 |
Pfizer Inc. |
Histamine-3 receptor antagonists
|
EP1945639A1
(en)
|
2005-11-04 |
2008-07-23 |
Pfizer Limited |
Tetrahydronaphthyridine derivative
|
WO2007063385A2
(en)
|
2005-12-01 |
2007-06-07 |
Pfizer Products Inc. |
Spirocyclic amine histamine-3 receptor antagonists
|
WO2007069053A1
(en)
|
2005-12-14 |
2007-06-21 |
Pfizer Products Inc. |
Benzimidazole antagonists of the h-3 receptor
|
WO2007088450A2
(en)
|
2006-02-01 |
2007-08-09 |
Pfizer Products Inc. |
Chromane antagonist of the h-3 receptor
|
WO2007088462A1
(en)
|
2006-02-01 |
2007-08-09 |
Pfizer Products Inc. |
Spirochromane antagonists of the h-3 receptor
|
WO2007099423A1
(en)
|
2006-03-02 |
2007-09-07 |
Pfizer Products Inc. |
1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
|
WO2007105053A2
(en)
|
2006-03-13 |
2007-09-20 |
Pfizer Products Inc. |
Tetralines antagonists of the h-3 receptor
|
GB0605462D0
(en)
|
2006-03-17 |
2006-04-26 |
Glaxo Group Ltd |
Novel compounds
|
BRPI0710658A2
(pt)
|
2006-04-21 |
2011-08-16 |
Pfizer Prod Inc |
compostos de piridina[3,4-b] pirazinonas, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos
|
WO2007138431A2
(en)
|
2006-05-30 |
2007-12-06 |
Pfizer Products Inc. |
Azabicyclic ether histamine-3 antagonists
|
US20080090834A1
(en)
|
2006-07-06 |
2008-04-17 |
Pfizer Inc |
Selective azole pde10a inhibitor compounds
|
US7745646B2
(en)
|
2006-07-07 |
2010-06-29 |
Kalypsys, Inc. |
Bicyclic heteroaryl inhibitors of PDE4
|
US8138205B2
(en)
|
2006-07-07 |
2012-03-20 |
Kalypsys, Inc. |
Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
|
ATE488520T1
(de)
|
2006-08-04 |
2010-12-15 |
Merz Pharma Gmbh & Co Kgaa |
Pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
|
EP1900739A1
(en)
|
2006-08-30 |
2008-03-19 |
Cellzome Ag |
Diazolodiazine derivatives as kinase inhibitors
|
WO2008033739A2
(en)
*
|
2006-09-12 |
2008-03-20 |
Neurogen Corporation |
Benzimidazole carboxamide derivatives
|
WO2008045663A2
(en)
|
2006-10-06 |
2008-04-17 |
Kalypsys, Inc. |
Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents
|
WO2008045664A2
(en)
|
2006-10-06 |
2008-04-17 |
Kalypsys, Inc. |
Heterocyclic pde4 inhibitors as antiinflammatory agents
|
US20080102475A1
(en)
|
2006-10-13 |
2008-05-01 |
Zhengyan Kan |
Alternatively spliced isoform of phosphodiesterase 4B (PDE4B)
|
CL2007002994A1
(es)
|
2006-10-19 |
2008-02-08 |
Wyeth Corp |
Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
|
WO2008056176A1
(en)
|
2006-11-10 |
2008-05-15 |
Scottish Biomedical Limited |
Pyrazolopyrimidines as phosphodiesterase inhibitors
|
SI2124933T1
(sl)
|
2007-01-22 |
2012-12-31 |
Pfizer Products Inc. |
Tosilatna sol terapevtske spojine in farmacevtski sestavi tega
|
US20090176778A1
(en)
|
2007-08-10 |
2009-07-09 |
Franz Ulrich Schmitz |
Certain nitrogen containing bicyclic chemical entities for treating viral infections
|
SG183699A1
(en)
|
2007-08-10 |
2012-09-27 |
Lundbeck & Co As H |
Heteroaryl amide analogues
|
EP2085398A1
(en)
|
2008-02-01 |
2009-08-05 |
Merz Pharma GmbH & Co. KGaA |
Pyrazolopyrimidines, a process for their preparation and their use as medicine
|
WO2009108551A2
(en)
|
2008-02-25 |
2009-09-03 |
H. Lundbeck A/S |
Heteroaryl amide analogues
|
GB2461702A
(en)
|
2008-07-08 |
2010-01-13 |
Dyson Technology Ltd |
Hand drying apparatus
|
US9643922B2
(en)
|
2008-08-18 |
2017-05-09 |
Yale University |
MIF modulators
|
WO2010034738A2
(en)
|
2008-09-24 |
2010-04-01 |
Basf Se |
Pyrazole compounds for controlling invertebrate pests
|
WO2010059836A1
(en)
|
2008-11-20 |
2010-05-27 |
Decode Genetics Ehf |
Substituted aza-bridged bicyclics for cardiovascular and cns disease
|
US20100204265A1
(en)
|
2009-02-09 |
2010-08-12 |
Genelabs Technologies, Inc. |
Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
|
EP2408446B1
(en)
|
2009-03-20 |
2019-09-11 |
HG&H Pharmaceuticals (Pty) Limited |
Use of pharmaceutical compositions containing mesembrenone
|
EP2493889B1
(en)
|
2009-10-30 |
2017-09-06 |
Janssen Pharmaceutica, N.V. |
IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
|
JP2013512216A
(ja)
|
2009-11-25 |
2013-04-11 |
メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン |
置換ピラゾロピリミジン類の結晶形
|
AR079451A1
(es)
|
2009-12-18 |
2012-01-25 |
Nycomed Gmbh |
Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
|
EP2549874A4
(en)
|
2010-03-23 |
2013-10-02 |
High Point Pharmaceuticals Llc |
SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
|
NZ603136A
(en)
|
2010-05-10 |
2014-11-28 |
Gilead Sciences Inc |
Bifunctional quinoline derivatives
|
AR081377A1
(es)
|
2010-05-10 |
2012-08-29 |
Gilead Sciences Inc |
Compuestos de pirazolopiridina bifuncionales
|
US8609669B2
(en)
|
2010-11-16 |
2013-12-17 |
Abbvie Inc. |
Potassium channel modulators
|
WO2013028263A1
(en)
|
2011-08-24 |
2013-02-28 |
Glaxosmithkline Llc |
Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
|
PE20151332A1
(es)
|
2013-02-19 |
2015-09-20 |
Pfizer |
Compuestos de azabencimidazol
|
WO2014200882A1
(en)
|
2013-06-11 |
2014-12-18 |
Janssen Pharmaceutica Nv |
PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES
|
GB201321734D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
CN115068134A
(zh)
|
2014-03-21 |
2022-09-20 |
阿莱恩技术有限公司 |
具有弹性体的分段的正畸矫正器
|
JP6713982B2
(ja)
|
2014-07-24 |
2020-06-24 |
ファイザー・インク |
ピラゾロピリミジン化合物
|
KR102061952B1
(ko)
|
2014-08-06 |
2020-01-02 |
화이자 인코포레이티드 |
이미다조피리다진 화합물
|